Arjun Goyal, MD, MPHIL, MBA

Co-Founder and Managing Director

Vida Ventures

Dr. Arjun Goyal is a co-founder and managing director of Vida Ventures, a leading US-based life sciences venture capital firm with a ~$1.8 billion in AUM. Arjun focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Arjun serves as a director on the boards of Scorpion Therapeutics, Quanta Therapeutics, and Alterome Therapeutics and as a co-founder and director, Affini-T Therapeutics. Furthermore, he has played key roles in Vida Venture’s investments in Homology Medicines (NASDAQ:FIXX), Pionyr Immunotherapeutics (acquired by Gilead), Peloton Therapeutics (acquired by Merck & Co.), and Asklepios Bio (acquired by Bayer).


Before co-founding Vida Ventures in 2017, Arjun was a life sciences investor at 5AM Ventures. Arjun received his BSc in Medical Science, Diploma in French and his MBBS degree from the Universities of Melbourne and Oxford. He completed his postgraduate clinical training in Internal Medicine in Sydney. He received his MPhil in Bioscience Enterprise from University of Cambridge and his MBA from Harvard Business School. Arjun has received multiple awards for his work including the Advance Award for Technology & Entrepreneurship from the Australian Government. He serves on the Committee for the American Australian Association Education Fellowship and is on the Board of Advisors of the MS/MBA Life Sciences Program at Harvard Business School where also serves as a Venture Capital Advisor.

Scroll to Top